摘要:
An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
摘要:
An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
摘要:
An object of the present invention is to develop and provide an epithelial ovarian cancer diagnosis marker with which epithelial ovarian cancer can be detected inexpensively, conveniently, and low invasively with high accuracy, and a method for determining the presence or absence of epithelial ovarian cancer using the marker. The present invention provides a glycoprotein having a glycan-linked asparagine residue at a particular site of the glycoprotein secreted from an epithelial ovarian cancer cell, or a fragment thereof having the glycan as an epithelial ovarian cancer diagnosis marker. The present invention also provides a method for determining the presence or absence of epithelial ovarian cancer using the glycoprotein.
摘要:
The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
摘要:
The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
摘要:
The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
摘要:
An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.
摘要:
An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.
摘要:
Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit thereof. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.
摘要:
Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit therefor. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision.